China, Taiwan acknowledge facing similar regulatory challenges

06/26/2013 | In-PharmaTechnologist.com

At the DIA 2013 49th Annual Meeting in Boston, health officials from China and Taiwan discussed the similar issues they face concerning evaluation and approval of new drugs, and seemed open to more interaction. Chinese official Yi Feng noted that his government's recent approval of a new drug based on testing in Taiwan and China might be a sign of future developments. The Chinese FDA plans to change its investigational new-drug regulations, while Taiwan is focused on approving INDs more quickly and encouraging more trials to be held locally.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY